Summary
Approximately 20 to 30% of patients with active intractable epilepsy are commonly treated with polytherapy antiepileptic drug regimens, and these patients may experience complicated drug interactions. Furthermore, because of the long term nature of treatment, the possibility of drug interactions with drugs used for the treatment of concomitant disease is high. Classically, clinically significant drug interactions, both pharmacokinetic and pharmacodynamic, have been considered to be detrimental to the patient, necessitating dosage adjustment. However, this need not always be the case. With the introduction of new drugs (e.g. vigabatrin and lamotrigine) with known mechanisms of action, the possibility exists that these can be used synergistically. The most commonly observed clinically significant pharmacokinetic interactions can be attributed to interactions at the metabolic and serum protein binding levels. The best known examples relate to induction (e.g. phenobarbital, phenytoin, carbamazepine and primidone) or inhibition [e.g. valproic acid (sodium valproate)] of hepatic monooxygenase enzymes.
The extent and direction of interactions between the different antiepileptic drugs are varied and unpredictable. Interactions in which the metabolism of phenobarbital, phenytoin or carbamazepine is inhibited are particularly important since these are commonly associated with toxicity. Some inhibitory drugs include macrolide antibiotics, chloramphenicol, cimetidine, isoniazid and numerous sulphonamides. A reduction in efficacy of antibiotic, cardiovascular, corticosteroid, oral anticoagulant and oral contraceptive drugs occurs during combination therapy with enzyme-inducing antiepileptic drugs. Discontinuation of the enzyme inducer or inhibitor will influence the concentrations of the remaining drug(s) and may necessitate dosage readjustment.
Similar content being viewed by others
References
Abbott FS, Kassam J, Orr MJ, Farrell K. The effect of aspirin on valproic acid metabolism. Clinical Pharmacology and Therapeutics 40: 94–100, 1986
Adebayo GI. Interaction between phenytoin and theophylline in healthy volunteers. Clinical and Experimental Pharmacology and Physiology 15: 888–889, 1988
Ahmad S. Renal insensitivity to frusemide caused by chronic antiepileptic therapy. British Medical Journal 3: 657–659, 1974
Ahmad S, Clarke L, Hewett, AJ, Richens A. Controlled trial of frusemide as an antiepileptic drug in focal epilepsy. British Journal of Clinical Pharmacology 3: 621–625, 1976
Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 34: 161–162, 1993
Albani F, Theodore WH, Washington P, Devinsky O, Bromfield E, et al. Effect of felbamate on plasma concentrations of carb-amazepine and its metabolites. Epilepsia 32: 130–132, 1991
Anderson GD, Levy RH. The effect of valproate on the metabolism of phenobarbital in the rat. Pharmaceutical Research 9: 1622–1628, 1992
Anhut H, Leppik I, Schmidt B, Thomann P. Drug interaction study of the new antiepileptic gabapentin with phenytoin in epileptic patients. Naunyn-Schmiedeberg’s Archives of Pharmacology 337 (Suppl.): 29, 1988
Arana GW, Goff DC, Friedman H. Does carbamazepine-induced reduction of plasma haloperidol concentrations worsen psychotic symptoms?. American Journal of Psychiatry 143: 650–651, 1986
Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML’E, et al. The effect of oral contraceptive steroids and enzymic inducing drugs on sex hormone binding globulin capacity in women. British Journal of Clinical Pharmacology 9: 115, 1980
Back DJ, Grimmer SFM, Orme ML’E, Proudlove C, Mann RD, et al. Evaluation of Committee on Safety of Medicines Yellow Card reports on oral contraceptive-drug interactions with antiepileptic drugs and antibiotics. British Journal of Clinical Pharmacology 25: 527–532, 1988
Bahls FH, Ozuna J, Ritchie DE. Interaction between calcium channel blockers and the antiepileptic drugs carbamazepine and phenytoin. Neurology 41: 740–742, 1991
Baillie TA. Metabolic activation of valproic acid and drug-mediated hepatotoxicity: role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chemical Research and Toxicology 1: 195–199, 1988
Bartle WR, Walker SE, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clinical Pharmacology and Therapeutics 33: 649–655, 1983
Battino D, Avanzini G, Bossi L, Groci D, Cusi C, et al. Plasma concentrations of primidone and its metabolite phenobarbital: effect of age and associated therapy. Therapeutic Drug Monitoring 5: 73–79, 1983
Battino D, Bossi L, Croci D, Franceschetti S, Gomeni C, et al. Carbamazepine plasma concentrations in children and adults: influence of age, dose and associated therapy. Therapeutic Drug Monitoring 2: 315–322, 1980
Battino D, Croci D, Granata T, Bernardi G, Monza G. Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine. Therapeutic Drug Monitoring 14: 376–379, 1992
Battino D, Cusi C, Franceschetti S, Moise A, Spina S, et al. Ethosuximide plasma concentrations: influence of age and associated concomitant therapy. Clinical Pharmacokinetics 7: 176–180, 1982
Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 32: 570–572, 1982
Beattie B, Biller J, Mehlhaus B, Murrey M. Verapamil-induced neurotoxicity. European Journal of Neurology 28: 104–105, 1988
Berg MJ, Fincham RW, Ebert BE, Schottelius DD. Phenytoin pharmacokinetics: before and after folic acid administration. Epilepsia 33: 712–720, 1992
Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clinical Pharmacokinetics 3: 128–143, 1978
Beurey J, Weber M, Vignaud JM. Treatment of tinea capitis: metabolic interference of griseofulvin with phenobarbital. Annales de Dermatologie et de Venereologie 109: 567–570, 1982
Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, de Korte RA, Meijer JWA, et al. Acute effects of lamotrigine (BW 430C) in persons with epilepsy. Epilepsia 27: 248–254, 1986
Bittencourt PRM, Cracia CM, Martins R, Fernandes AG, Diekmann HW, et al. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology 42: 492–496 1992
Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, et al. Effect of fluconazole on the disposition of phenytoin. Clinical Pharmacology and Therapeutics 49: 420–425, 1991
Bochner F, Hooper WD, Tyrer JH, Eadie MJ. The effect of dosage increments on blood phenytoin concentrations. Journal of Neurology, Neurosurgery and Psychiatry 35: 873–876, 1972
Boobis AR, Davies DS. Human cytochromes P-450. Xenobiotica 14: 151–185, 1984
Bourgeois BFD. Antiepileptic potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clinical Neuropharmacology 11: 348–359, 1988
Bourgeois BFD, Dodson WE, Ferrendelli JA. Interaction between primidone, carbamazepine and nicotinamide. Neurology 32: 1122–1126, 1982
Bourgeois BFD, Dodson WE, Ferrendelli JA. Primidone, phenobarbitone and PEMA: II. Seizure protection, neurotoxicity, and therapeutic index of varying combinations in mice. Neurology 33: 291–295, 1983
Bourgeois BFD, Wad N. Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity. Epilepsia 29: 482–487, 1988
Braithwaite RA, Flanagan RA, Richens A. Steady state plasma nortriptyline concentrations in epileptic patients. British Journal of Clinical Pharmacology 2: 469–471, 1975
Breckenridge A. Drug interactions with oral anticoagulants. British Medical Journal 2: 397–400, 1974
Brodie MJ. Management of epilepsy during pregnancy and lactation. Lancet 336: 426–427, 1990a
Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. Lancet 336: 350–354, 1990b
Brodie MJ, Forrest G, Rapeport WG. Carbamazepine-10, 11-epoxide concentrations in epileptics on carbamazepine alone and in combination with other antiepileptic drugs. British Journal of Clinical Pharmacology 16: 747–750, 1983
Brodie MJ, Macphee GJA. Carbamazepine neurotoxicity precipitated by diltiazem. British Medical Journal 292: 1170–1171, 1986
Brooks SM, Buchanan WW, Grove M, Downie NW. Effects of enzyme-induction on metabolism of prednisolone: clinical and laboratory study. Annals of the Journal of Rheumatic Diseases 291: 339–343, 1976
Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. New England Journal of Medicine 286: 1125–1128, 1972
Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, et al. Vigabatrin for refractory complex partial seizures: multi-centre single-blind study with long term follow up. Neurology 37: 184–189, 1987
Browne TR, Szabo GK, Evans JE, Evans BA, Greenblatt DJ, et al. Carbamazepine increases phenytoin serum concentration and reduces phenytoin clearance. Neurology 38: 1146–1150, 1988
Bruni J, Wilder BJ, Perchalski RJ, Hammond EJ, Villareal HJ. Valproic acid and plasma concentrations of phenobarbital. Neurology 30: 94–97, 1980
Capewell S, Freestone J, Critchley JAJH, Potlage A, Prescott LF. Reduced felodipine bioavailability in patients taking antiepileptic drugs. Lancet 2: 480–482, 1988
Caranasos GJ, Stewart RB, Cluff LE. Clinical desirable drug interactions. Annual Reviews in Pharmacology and Toxicology 25: 67–97, 1985
Carl GF, Smith ML. Phenytoin-folate interaction: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia 33: 372–375, 1992
Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. Therapeutic Drug Monitoring 3: 333–340, 1981
Carstensen H, Jacobsen N, Dieperink H. Interaction between cyclosporin A and phenobarbitone. British Journal of Clinical Pharmacology 21: 550–551, 1986
Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, et al. The efficacy of carbamazepine combinations in epilepsy. Clinical Pharmacology and Therapeutics 18: 733–741, 1975
Cereghino JJ, von Meter JC, Brook JT, Penry JK, Smith LD, et al. Preliminary observations of serum carbamazepine concentrations in epileptic patients. Neurology 23: 357–366, 1973
Chalk JB, Ridgeway K, Brophy T, Yelland JDN, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. Journal of Neurology Neurosurgery and Psychiatry 47: 1087–1090, 1984
Chang T. Ethosuximide: absorption, distribution and excretion. In Levy et al. (Eds) Antiepileptic drugs, pp. 671–678, Raven Press, New York, 1989
Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine concentrations in patients with epilepsy. Acta Neurologica Scandinavica 49: 543–546, 1973
Cloyd JC, Leppik IE. Primidone: absorption, distribution and excretion. In Levy et al. (Eds) Antiepileptic drugs, pp. 391–400, Raven Press, New York, 1989
Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, et al. Lamotrigine, a new antiepileptic: pharmacokinetics in normal humans. Clinical Pharmacology and Therapeutics 42: 535–541, 1987
Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacological Reviews 19: 317–366, 1967
Cosh DG, Rowett DS, Lee PC, McCarthy PJ. Case report: phenytoin therapy complicated by concurrent chloramphenicol and enterai nutrition. Australian Journal of Hospital Pharmacy 17: 51–53, 1987
Couet W, Istin B, Ingrand I, Girault J, Fourtillan JB. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Therapeutic Drug Monitoring 12: 144–149, 1990
Coulam CB, Annegers JF. Do antiepileptic drugs reduce the efficacy of oral contraceptives?. Epilepsia 20: 519–525, 1979
Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole and multi drug therapy. Therapeutic Drug Monitoring 8: 411–416, 1986
Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. British Journal of Clinical Pharmacology 30: 892–896, 1990
Crowley JJ, Cusack BJ, Jue SG, Koup JR, Park BK, et al. Aging and drug interactions: II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. Journal of Pharmacology and Experimental Therapeutics 245: 513–523, 1988
Crowley JJ, Cusack BJ, Jue SG, Koup JR, Vestal RE. Cigarette smoking and theophylline metabolism: effect of phenytoin. Clinical Pharmacology and Therapeutics 42: 334–340, 1987
Cucinell SA, Conney AH, Sansur M, Burns JJ. Drug interactions in man: 1. Lowering effect of phenobarbital on plasma concentrations of bishydroxycoumarin (Dicoumarol) and diphenylhydantoin (Dilantin). Clinical Pharmacology and Therapeutics 6: 420–429, 1965
Dalton MJ, Powell JR, Messenheimer JA, Clark J. Cimetidine and carbamazepine, a complex drug interaction. Epilepsia 27: 553–558, 1986
Dam M, Kristensen CB, Hansen BS, Christiansen J. Interaction between carbamazepine and propoxyphene in man. Acta Neurologica Scandinavica 56: 603–607, 1977
D’Arcy PF, McElnay JC. Drug-antacid interactions of clinical importance. Drug Intelligence and Clinical Pharmacy 21: 607–617, 1987
Dasgupta A, Dennen DA, Dean R, McLawhon RW. Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcilllin and sulfamethoxazole. Clinical Chemistry 37: 98–100, 1991
Davis M, Simmons CJ, Harrison NG, Williams R. Paracetamol overdose in man: relationship between pattern of urinary metabolites and severity of liver damage. Quarterly Journal of Medicine 45: 181–191, 1976
De Leacy EA, McLeay CD, Eadie MJ, Tyrer JH. Effects of subjects’ sex and intake of tobacco, alcohol and oral contraceptives on plasma phenytoin concentrations. British Journal of Clinical Pharmacology 8: 33–36, 1979
Depot M, Powell JR, Messenheimer JA, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clinical Pharmacology and Therapeutics 48: 346–355, 1990
Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. British Journal of Clinical Pharmacology 13: 553–560, 1982
Dockweiler V. Isoniazid-induced valproic acid toxicity or vice versa. Lancet 2: 152, 1987
Døssing M, Pilsgaad H, Rasmussen B, Enghusen-Poulsen H. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. European Journal of Clinical Pharmacology 25: 215–222, 1983
Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 37: 379–385, 1987
Duncan JS, Patsalos PN, Shorvon SD. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. Epilepsia 32: 101–115, 1991
Eadie MJ, Lander CM, Hooper WD, Tyrer JH. Factors influencing plasma phenobarbitone concentrations in epileptic patients. British Journal of Clinical Pharmacology 4: 541–547, 1977
Eadie MJ, McKinnon GE, Dunstan PR, MacLaulin D, Dickinson RG. Valproate metabolism during hepatotoxicity associated with the drug. Quarterly Journal of Medicine 77: 1229–1240, 1990
Eichelbaum M, Kothe KW, Hoffman F, Von Unruh GE. Kinetics and metabolism of carbamazepine during combined antiepileptic therapy. Clinical Pharmacology and Therapeutics 26: 367–371, 1979
Fincham RW, Schottelius DD. Decreased phenytoin concentrations in antineoplastic therapy. Therapeutic Drug Monitoring 1: 277–283, 1979
Fincham RW, Schottelius DD, Sahs AL. The influence of di-phenylhydantoin on primidone metabolism. Archives of Neurology 30: 259–262, 1974
Fine A, Henderson IS, Morgan DR, Tilstone WJ. Malabsorption of frusemide caused by phenytoin. British Medical Journal 2: 1061–1062, 1977
Fleitman JS, Bruni J, Perrin JH, Wilder BJ. Albumin binding interactions of sodium valproate. Journal of Clinical Pharmacology 20: 314–317, 1980
Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, et al. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia 29: 488–491, 1988
Fuji K, Hayashi M, Murata R. Effect of diphenylhydantoin on plasma 11-0 CH5: interference in the effects of dexamethasone and metapyrone. Brain Development 7: 354–360, 1975
Garrettson LK, Perel JM, Dayton PG. Methylphenidate interactions with both antiepileptic and ethyl-biscoumacetate. Journal of the American Medical Association 207: 2053–2056, 1969
Gay PE, Madsen JA. Interactions between phenobarbital and thioridazine. Neurology 33: 631–632, 1983
Geaney DP, Carver JG, Davies CL, Aronson JK. Pharmacokinetic investigation of the interaction of azopropazone with phenytoin. British Journal of Clinical Pharmacology 15: 724–734, 1983
Gillham RA, Williams N, Weidmann K, Butler E, Larkin JG, et al. Concentration-effect relationship with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. Journal of Neurology, Neurosurgery and Psychiatry 51: 929–933, 1988
Glacona N, Bauman, JL, Siepler IK. Crystallization of three phenytoin preparations in intravenous fluids. American Journal of Hospital Pharmacy 32: 630–634, 1982
Goldbaum LR, Smith PK. The interaction of barbiturates with serum albumin and its possible relation to their disposition and pharmacological actions. Journal of Pharmacology and Experimental Therapeutics 111: 197–204, 1954
Gore JM, Haffajee CI, Alpert JS. Interaction of amiodarone and diphenylhydantoin. American Journal of Cardiology 54: 1145, 1984
Goulden KJ, Camfield P, Dooley JM, Fraser A, Meek DC, et al. Severe carbamazepine intoxication after coadministration of erythromycin. Journal of Pediatrics 109: 135–138, 1986
Goulden KJ, Dooley JM, Camfield PR, Fraser AD. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 37: 1392–1394, 1987
Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 30: 225–229, 1989
Grimaldi R, Lecchini S, Crema F, Perucca E. In vivo plasma protein binding interaction between valproic acid and naproxen. European Journal of Drug Metabolism and Pharmacokinetics 9: 359–363, 1984
Grimsley SR, Jann MW, Carter JG, D’Mello AP, D’souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clinical Pharmacology and Therapeutics 50: 10–15, 1991
Guelen PJM, Van Der Kleijn E, Woudstra V. Statistical analysis of pharmacokinetic parameters in epileptic patients chronically treated with antiepileptic drugs. In Schneider et al. (Eds) Clinical pharmacology of antiepileptic drugs, pp. 2–10, Springer-Verlag, Berlin, 1975
Gupta AK, Jeavons PM. Complex partial seizures: EEG foci and response to carbamazepine and sodium valproate. Journal of Neurology, Neurosurgery and Psychiatry 48: 1010–1014, 1985
Haegele KD, Schechter PJ. Kinetics of enantiomers of vigabatrin after an oral dose of the racemate or active S-enantiomer. Clinical Pharmacology and Therapeutics 40: 581–585, 1986
Hansen BS, Dam M, Brandt J, Hvidberg EF, Angelo H. Influence of dextropropoxyphene on steady-state serum concentrations and protein binding of three anti-epileptic drugs. Acta Neurologica Scandinavica 61: 357–367, 1980
Hansen JM, Siersbaek-Nielsen K, Kristensen M, Skovsted L, Christensen LK. Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Medica Scandinavica 189: 15–19, 1971a
Hansen JM, Siersboek-Nielsen KJ, Skovsted L. Carbamazepine-induced acceleration of diphenylthydantoin and warfarin metabolism in man. Clinical Pharmacology and Therapeutics 12: 536–543, 1971b
Hansson O, Sillanpaa M. Pyridoxine and serum concentrations of phenytoin and phenobarbitone. Lancet 1: 258, 1976
Hayden M, Buchanan NH. Danazol: carbamazepine interaction. Medical Journal of Australia 155: 851, 1991
Haydukewyck D, Rodin EA. Effects of phenothiazine on serum antiepileptic drug concentrations in psychiatric patients with seizure disorders. Therapeutic Drug Monitoring 7: 401–405, 1985
Heckmatt J, Shaikh AA, Swash M, Scott DF. Seizure induction by alcohol in patients with epilepsy: experience in two hospital clinics. Journal of the Royal Society of Medicine 83: 6–9, 1990
Hedrick R, Williams F, Marin R, Lamb WA, Cate JC. Carbamazepine-erythromycin interaction leading to carbamazepine toxicity in four epileptic children. Therapeutic Drug Monitoring 5: 405–407, 1983
Heijertz R, Pilz H. Interaction of nitrofurantoin with diphenylhydantoin. Journal of Neurology 218: 297–301, 1978
Hendeles L. Decreased oral phenytoin absorption following concurrent theophylline administration. Journal of Allergy and Clinical Immunology 63: 156, 1979
Hoppener RJ, Kuyer A, Meijer JWA, Hulsman J. Correlation between daily fluctuations of carbamazepine serum concentrations and intermittent side effects. Epilepsia 21: 341–350, 1980
Houtkooper MA, Lammertsma A, Meyer JWA, Goedhart DM, Meinardi H, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?. Epilepsia 28: 693–698, 1987
Hoyampa AM, Schenker S. Major drug interactions: effects of liver disease, alcohol and malnutrition. Annual Review of Medicine 33: 113–149, 1982
Huisman JW, van Heycop Ten Ham MW, van Zijl CHM. Influence of ethylphenacemide on serum concentrations of other antiepileptic drugs. Epilepsia 11: 207–215, 1970
Hurwitz A. Antacid therapy and drug kinetics. Clinical Pharmcokinetics 2: 269–280, 1977
Ishizaki T, Chiba K, Saito M, Kobavashi K, Izuka R. The effect of neuroleptics (haloperidol and chlorpromazine) on the phar-macokinetics of valproic acid in schizophrenic patients. Journal of Clinical Psychopharmacology 4: 254–261, 1984
Isojarvi JIT, Parkarinen AJ, Ylipalosaari PJ, Myllyla VV. Serum hormones in male epileptic patients receiving antiepileptic medications. Archives of Neurology 47: 670–676, 1990
Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, et al. Effects of carbamazepine on haloperidol concentrations. Journal of Clinical Psychopharmacology 5: 106–109, 1985
Jann MW, Fidone GS, Israel MK, Bonadero P. Increased valproate serum concentrations upon carbamazepine cessation. Epilepsia 29: 578–581, 1988
Jawad CD, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, et al. Lamotrigine: single-dose pharmacokinetics and initial one week experience in refractory epilepsy. Epilepsy Research 1: 194–201, 1987
Jonkman JHG, Upton RA. Pharmacokinetic drug interactions with theophylline. Clinical Pharmacokinetics 9: 309–334, 1984
Jonville AP, Gauchez AS, Autret E, Billard C, Burkier P, et al. Interaction between isoniazid and valproate: a case of valproate overdosage. European Journal of Clinical Pharmacology 40: 197–198, 1991
Jubiz W, Meikle AW, Levinson RA, Mizutani S, West CD. Effect of diphenylhydantoin on the metabolism of dexamethasone. New England Journal of Medicine 283: 11–14, 1970
Kaneko S, Otani K, Fukushima Y, Ogawa Y, Nomura Y, et al. Teratogenciity of antiepileptic drugs: an analysis of possible risk factors. Epilepsia 29: 459–467, 1988
Kapetanovic IM, Kupferberg HJ. Inhibition of microsomal phenobarbital metabolism by valproic acid. Biochemical Pharmacology 30: 1361–1363, 1981
Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, et al. Mechanism of valproate-phenobarbital interaction in epileptic patients. Clinical Pharmacology and Therapeutics 29: 480–486, 1981
Karlen B, Garle M, Rane A, Gutova M, Lindborg B. Assay of the major (4-hydroxylated) metabolites of diphenylhydantoin in human urine. European Journal of Clinical Pharmacology 8: 359–363, 1975
Kater RMH, Roggin G, Tobon F, Zieve P, Iber FL. Increased rate of clearance of drugs from the circulation of alcoholics. American Journal of Medical Sciences 258: 35–39, 1969
Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JEM, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. British Journal of Clinical Pharmacology 20: 323–326, 1985
Kelly WN, Richardson AP, Mason MR, Rector FC. Acetazol-amide in phenobarbital intoxication. Archives of Internal Medicine 117: 64–69, 1966
Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. Journal of Clinical Psychopharmacology 12: 276–281, 1992
Koup JR, Gibaldi M, McNamara P, Hilligoss DM, Coburn WA, et al. Interaction of chloramphenicol with phenytoin and phenobarbital. Clinical Pharmacology and Therapeutics 24: 571–575, 1978
Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol interaction: its mechanism examined by stable isotape technique. Therapeutic Drug Monitoring 8: 387–392, 1986
Krasinski K, Kusmiesz M, Nelson JD. Pharmacological interactions among chloramphenicol, phenytoin and phenobarbitone. Pediatrie Infectious Disease Journal 1: 232–235, 1982
Kubacka RT, Ferrante JA. Carbamazepine-propoxyphene interaction. Clinical Pharmacy 2: 104, 1983
Kulshrestha VK, Thomas M, Wadsworth J, Richens A. Interaction between phenytoin and antacids. British Journal of Clinical Phamacology 6: 177–179, 1978
Kurata D, Wilkinson GR. Erythrocyte uptake and plasma binding of diphenylhydantoin. Clinical Pharmacology and Therapeutics 16: 355–362, 1974
Kutt H, Brennan R, Dehejia H, Verebely K. Diphenylhydantoin intoxication, a complication of isoniazid therapy. American Review of Respiratory Disease 101: 377–388, 1970
Kutt H, Hanes M, Verebely K, McDowell F. The effect of phenobarbital on plasma diphenylhydantoin concentration and metabolism in man and rat liver microsomes. Neurology 19: 611–616, 1969
Kutt H, Verebely K. Metabolism of diphenylhydantoin by rat liver microsomes: 1. Characteristics of the reaction. Biochemical Pharmacology 19: 675–686, 1970
Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clinical Pharmacology and Therapeutics 25: 316–323, 1978
Lai ML, Lin TS, Huang JD. Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. European Journal of Clinical Pharmacology 43: 201–203, 1992
Lambie DG, Johnson RH. The effect of phenytoin on phenobarbitone and primidone metabolism. Journal of Neurology, Neurosurgery and Psychiatry 44: 148–151, 1981
Leonard RF, Knott PJ, Huntington W, Rankin GO, Robinson DS, et al. Phenytoin-salicylate interaction. Clinical Pharmacology and Therapeutics 29: 56–60, 1981
Lesko LJ, Ruangtrakool T. In vitro displacement of phenytoin from protein binding sites by amiodarone. Clinical Pharmacology and Therapeutics 41: 238, 1987
Levi AJ, Sherlock S, Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 2: 1275–1279, 1968
Levine M, Jones MW, Sheppard I. Differential effects of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology 35: 562–565, 1985
Levy G, Yamoda H. Drug biotransformation interactions in man: II. Acetaminophen and salicylamide. Journal of Pharmaceutical Sciences 60: 215–221, 1971
Levy RH, Kerr B, Loiseau P, Guyot M, Wilensky A. Inhibition of carbamazepine epoxide elimination by valpromide and valproic acid. Epilepsia 27: 592, 1986
Levy RH, Martinez-Lage JM, Tor J, Blaut H, Gonzalez I, et al. Stiripentol concentration-dose relationship and interaction with carbamazepine in epileptic patients. Epilepsia 26: 544–555, 1985
Lewis R. Effect of barbiturates on anticoagulant therapy. New England Journal of Medicine 274: 110, 1966
Lindhout D, Hoppener RJEA, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation of carbamazepine. Epilepsia 25: 77–83, 1984
Linnoila M, Viukari M, Vaisanen K, Anvinen J. Effects of antiepileptic drugs on plasma haloperidol and thioridazine concentrations. American Journal of Psychiatry 137: 819–821, 1980
Liu SJ, Wang RIH. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. American Journal of Psychiatry 141: 1287–1288, 1984
Loga S, Curry S, Lader M. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. British Journal of Clinical Pharmacology 2: 197–208, 1975
Loscher W. A comparative study of the protein binding of antiepileptic drugs in serum of dogs and man. Journal of Pharmacology and Experimental Therapeutics 208: 429–435, 1979
Loscher W, Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid: antiepileptic and toxic potencies in mice. Neuropharmacology 24: 427–435, 1985
Ludgate J, Keating J, O’Dwyer R, Callaghan N. An improvement in cognitive function following polypharmacy reduction in a group of epileptic patients. Acta Neurologica Scandinavica 71: 448–452, 1985
Lunde PKM, Rane A, Yaffe SJ, Lund L, Sjöqvist F. Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clinical Pharmacology and Therapeutics 11: 846–855, 1970
MacCallum WAG. Interaction of lithium and phenytoin. British Medical Journal 280: 610–611, 1980
MacCosbe PE, Toomey K. Interaction of phenytoin and folic acid. Clinical Pharmacy 2: 362–369, 1983
MacDonald MG, Robinson DS. Clinical observations on possible barbiturate interference with anticoagulation. Journal of the American Medical Association 204: 95–99, 1968
Macphee GJA, Mclnnes GT, Thompson GG, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1: 700–703, 1986
Marquis JF, Carruthers SG, Spence JD, Brownstone YS, Toogood JH. Phenytoin-theophylline interaction. New England Journal of Medicine 307: 1189–1190, 1982
Mattson RH, Cramer JA. Valproic acid and ethosuximide interaction. Annals of Neurology 7: 583–584, 1980
Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. Journal of the American Medical Association 256: 238–240, 1985
Mattson RH, Gallagher BB, Reynolds EH, Glass D. Folate therapy in epilepsy: a controlled study. Archives of Neurology 29: 78–81, 1973
Mauro LS, Mauro VF, Brown DL, Somani P. Enhancement of phenytoin elimination by multiple-dose activated charcoal. Annals of Emergency Medicine 16: 1132–1135, 1987
McAuliffe JJ, Sherwin AL, Leppick IE, Fayle SA, Pippenger CE. Salivary concentrations of antiepileptic drugs: a practical approach to drug monitoring. Neurology 27: 409–413, 1977
McGovern B, Geer VR, LaRaia PJ, Garan H, Ruskin JN. Possible interaction between amiodarone and phenytoin. Annals of Internal Medicine 101; 650–651, 1984
McKee PJW, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Research 11: 193–198, 1992
Mesdjian E, Dravet C, Cenraud B, Roger J. Carbamazepine interaction due to triacetyloleandomycin administration in epileptic patients. Epilepsia 21: 489–496, 1980
Miller RR, Porter J, Greenblatt DJ. Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program. Chest 75: 356–358, 1979
Mireles R, Leppik IE. Valproate and clonazepam comedication in patients with intractable epilepsy. Epilepsia 26: 122–126, 1985
Mitchell AS, Holland JT. Fluconazole and phenytoin: a predictable interaction. British Medical Journal 298: 1315, 1989
Molholm Hansen J, Kampmann JP, Siersbaek-Nielsen K, Lum-holtz IB, Arrow M, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Medica Scandinavica 624(Suppl. 1): 106–110, 1979
Morselli PL. Carbamazepine absorption, distribution and excretion. In Levy et al. (Eds) Antiepileptic drugs, pp. 473–490, Raven Press, New York, 1989
Morselli PL, Rizzo M, Garattini S. Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Annals of the New York Academy of Science 179: 88–107, 1971
Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 21: 663–680, 1980
Nappi J. Warfarin and phenytoin interaction. Annals of Internal Medicine 90: 852, 1979
Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and antiepileptic drugs. Clinical Pharmacology and Therapeutics 43: 372–375, 1988
Neuvonen PJ, Elfving SM, Elonen E. Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. European Journal of Clinical Pharmacology 13: 213–218, 1978
Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. European Journal of Clinical Pharmacology 17: 51–57 1980
Neuvonen PJ, Lehtovarra R, Bardy A, Elomaa E. Antipyretic analgesics in patients on antiepileptic drug therapy. European Journal of Clinical Pharmacology 15: 263–268, 1979
Nishimura LY, Armstrong EP, Plezia PM, Iacono RP. Influence of enterai feedings on phenytoin sodium absorption from capsules: Drug Intelligence and Clinical Pharmacy 22: 130–133, 1988
O’Brien LS, Orme MLE, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. British Journal of Clinical Pharmacology 6: 176–177, 1978
Olanow CW, Finn AL, Prussak C. The effect of salicylate on the pharmacokinetics of phenytoin. Neurology 31: 341–342, 1981
Oles KS, Miza W, Penry JK. Catastrophic neurological signs due to drug interaction: Tegretol and Darvon. Surgical Neurology 32: 144–151, 1989
Ornstein E, Matteo RS, Schwartz AE, Silverberg PA, Young WL, et al. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 67: 191–196, 1987
Ornstein E, Matteo RS, Young WL, Diaz J. Resistance to me-tocurine-induced neuromuscular blockade in patients receiving phenytoin. Anesthesiology 63: 294–298, 1985
Panayiotopoulos GP, Feme CD, Knott C, Robinson RO. Interaction with lamotrigine and sodium valproate. Lancet 341: 445, 1993
Parson DM, Miles DW. Metabolic studies with BW 430C. Epilepsia 25: 655, 1984
Patel JH, Levy RM, Cutler RE. Phenobarbital-valproic acid interaction in normal man. Clinical Pharmacology and Therapeutics 27: 515–521, 1980
Patsalos PN. Antiepileptic drugs, hormones and seizure threshold. In Trimble (Ed.) Women and epilepsy, pp. 135–144, John Wiley & Sons Ltd, Chichester, 1991
Patsalos PN, Alavijeh MS, Brownhill W, Lascelles PT. Effect of denzimol on carbamazepine and carbamazepine-10,11-epox-ide concentrations in serum, liver, spleen and different brain regions of the rat: an inhibitory metabolic interaction. Nau-nyn-Schmiedeberg’s Archives of Pharmacology 337: 111–114, 1988a
Patsalos PN, Duncan JS, Shorvon SD. Effect of removal of individual antiepileptic drugs on antipyrine kinetics in patients taking polytherapy. British Journal of Clinical Pharmacology 26: 253–259, 1988b
Patsalos PN, Elyas AA, Zakzewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. European Journal of Clinical Pharmacology 39: 413–415, 1990a
Patsalos PN, Lascelles PT. In vitro hydroxylation of diphenylhydantoin and its inhibition by other commonly used antiepileptic drugs. Biochemical Pharmacology 26: 1929–1933, 1977a
Patsalos PN, Lascelles PT. Effect of sodium valproate on plasma protein binding of diphenylhydantoin. Journal of Neurology, Neurosurgery and Psychiatry 40: 570–574, 1977b
Patsalos PN, Lascelles PT. Inhibition of in vitro diphenylhydantoin hydroxylation by various antiepileptic drug combinations: a kinetic analysis. General Pharmacology 12: 51–55, 1981
Patsalos PN, Lascelles PT. Effect of sodium valproate and ethosuximide on phenobarbital plasma protein binding. Neurology 32: 1052–1053, 1982
Patsalos PN, Shorvon SD, Elyas AA, Smith G. The interaction of denzimol (a new antiepileptic) with carbamazepine and phenytoin. Journal of Neurology, Neurosurgery and Psychiatry 48: 374–377, 1985a
Patsalos PN, Stephenson TJ, Krishna S, Elyas AA, Lascelles PT, et al. Side-effects induced by carbamazepine-10,11-epoxide. Lancet 2: 496, 1985b
Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine?. European Journal of Clinical Pharmacology 39: 187–188, 1990b
Pearce GA. Apparent inhibition of phenytoin absorption by an enterai nutrient formula. Australian Journal of Hospital Pharmacy 18: 289–292, 1988
Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 23: 106–131, 1992
Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, et al. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clinical Pharamcology and Therapeutics 28: 779–789, 1980
Perucca E, Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. British Journal of Clinical Pharmacology 7: 201–206, 1979a
Perucca E, Richens A. Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. British Journal of Clinical Pharmacology 8: 21–31, 1979b
Pisani F, Fazio A, Oteri G, Perucca E, Trio R, et al. Carbam-azepine-viloxazine interaction in patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 49: 1142–1145, 1986a
Pisani F, Fazio A, Oteri G, Ruello G, Gitto C, et al. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 27: 548–552, 1986b
Pisani F, Fazio A, Oteri G, Spira A, Perucca E, et al. Effect of valpromide on the pharmacokinetics of carbamazepine-10,11-epoxide. British Journal of Clinical Pharmacology 25: 611–613, 1988
Pisani F, Narbone MC, Trunifio C, Fazio A, La Rosa G, et al. Valproic acid-ethosuximide interaction: a pharmacokinetic study. Epilepsia 25: 229–233, 1984
Pond SM, Kretschzmar KM. Effect of phenytoin on meperidine clearance and nor-meperidine formation. Clinical Pharmacology and Therapeutics 30: 680–686, 1981
Powell JR, Nelson E, Conrad KA, Likes K, Byers J, et al. Phenobarbital clearance, elimination with alkaline diuresis, and bioavailability in adults. Clinical Pharmacology and Therapeutics 29: 273–274, 1981
Prescott LF. Clinically important drug interactions. In Avery (Ed.) Drug treatment: principles and practice of clinical pharmacology and therapeutics, 2nd ed., pp. 236–262, ADIS Press, Auckland, 1980
Prescott LF, Critchley JAJH, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. British Journal of Clinical Pharmacology 12: 149–154, 1981
Prichard PJ, Walt RP, Kitchingman GK, Somerville KW, Langman MJS, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. British Journal of Clinical Pharmacology 24: 543–545, 1987
Reilly MJ. Drug information digest: methotrexate USP (amethopterin) and methotrexate sodium. American Journal of Hospital Pharmacy 30: 543–548, 1973
Rambeck B. Pharmacological interactions of methsuximide with phenobarbital and phenytoin in hospitalised epileptic patients. Epilepsia 20: 147–156, 1979
Rambeck B, May T, Juergens U. Serum concentrations of carb-amazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Therapeutic Drug Monitoring 9: 298–303, 1987
Rambeck B, Salke-Treumann A, May T, Boenigk HE. Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents. European Neurology 30: 79–83, 1990
Rameis H. On the interaction between phenytoin and digoxin. European Journal of Clinical Pharmacology 29: 49–53, 1985
Ramsey RE, McManus DQ, Guterman A, Briggle TV, Vazquez D, et al. Carbmazepine metabolism in humans: effect of concurrent antiepileptic therapy. Therapeutic Drug Monitoring 12: 235–241, 1990
Reed RC, Schwartz HJ. Phenytoin-theophylline-quinidine interaction. New England Journal of Medicine 308: 724–725, 1983
Reilly MJ. Drug information digest: methotrexate USP (ameth-opterin) and methotrexate sodium. American Journal of Hospital Pharmacy 30: 543–548, 1973
Remmer H, Hirschmann J, Greiner J. Die Bedeutung von Kumulation und Elimination für die Dosierung von Phenytoin (Diphenylhydantoin). Deutsche Medizinische Wochenschrift 94: 1265–1272, 1969
Reunanen MI, Luoma P, Myllyla VV, Hokkanen E. Low serum valproic acid concentrations in epileptic patients on combination therapy. Current Therapeutic Research 28: 455–462, 1980
Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 342: 185–186, 1993
Rey E, Pons G, Olive G. Vigabatrin clinical pharmacokinetics. Clinical Pharmacokinetics 23: 267–278, 1992
Reynolds EH. Folate and epilepsy. In Bradford & Marsden (Eds) Biochemistry and neurology, pp. 247–252, Academic Press, London, 1976
Richens A, Dunlop A. Serum phenytoin concentrations in management of epilepsy. Lancet 2: 247–248, 1975
Riegelman S, Rowland M, Epstein WL. Griseofulvin-phenobarbital interaction in man. Journal of the American Medical Association 213: 426–431, 1970
Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. British Journal of Clinical Pharmacology 27 (Suppl. 1): S27–S33, 1989
Riva R, Albani F, Contin M, Perucca E, Ambrosetto G, et al. Time-dependent interaction between phenytoin and valproic acid. Neurology 35: 510–515, 1985
Riva R, Contin M, Albani F, Perucca A, Procaccianti G, et al. Free concentrations of carbamazepine and carbamazepine-10,11-epoxide in children and adults: influence of age and phenobarbitone co-medication. Clinical Pharmacokinetics 10: 524–531, 1985
Robins DK, Wedlund PJ, Kuhn R, Baumann RJ, Levy RH, et al. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. British Journal of Clinical Pharmacology 29: 759–762, 1990
Roe TF, Podosin RL, Blaskovics ME. Drug interaction: diazoxide and diphenylhydantoin. Journal of Pediatrics 87: 480–484, 1975
Rolan PE, Somogyi AA, Drew MR, Cobain WG, South D, et al. Phenytoin intoxication during treatment with parenteral miconazole. British Medical Journal 287: 1760, 1983
Roth S, Ebrahim ZY. Resistance to pancuronium in patients receiving carbamazepine. Anesthesiology 66: 691–693, 1987
Routledge PA, Stargel WW, Finn AL, Barchowsky A, Shand DG. Lignocaine disposition in blood in epilepsy. British Journal of Clinical Pharmacology 12: 663–666, 1981
Rowan AJ, Meijer JWA, de Beer-Pawlinkowski N, van der Geest P, Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Archives of Neurology 40: 797–802, 1983
Rowland M, Gupta SK. Cyclosporin-phenytoin interaction: re-evaluation using metabolite data. British Journal of Clinical Pharmacology 24: 329–334, 1987
Sackellares JC, Sato S, Dreifuss FE, Penry JK. Reduction of steady state valproate concentrations by other antiepileptic drugs. Epilepsia 27: 437–441, 1981
Salem RB, Breland BD, Mishra SK, Jordan GE. Effect of cimetidine on phenytoin serum concentration. Epilepsia 24: 284–288, 1983
Salem SAM, Rajjayabun P, Shepherd AMM, Stevenson IH. Reduced induction of drug metabolism in the elderly. Age and Ageing 7: 68–73, 1978
Sambol NC, Upton RA, Chremos AN, Lin ET, Williams RL. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow. British Journal of Clinical Pharmacology 27: 83–87, 1989
Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research 6: 221–226, 1990a
Sander JWAS, Trevisol-Bittencourt PC, Hart YM, Patsalos PN, Shorvon SD. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Research 7: 226–229, 1990b
Sato J, Sekizawa Y, Yoshida A, Owada E, Sakuta N, et al. Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. Journal of Pharmacobiology-Dynamics 15: 467–472, 1992
Scheffner D, Konig ST, Reuterberg-Ruland I, Kochern W, Hofmann, et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia 29: 530–542, 1988
Schneider H. Carbamazepine: the influence of other antiepileptic drugs on its serum concentration. In Schneider et al. (Eds) Clinical pharmacology of antiepileptic drugs, pp. 189–195, Springer-Verlag, Berlin, 1975
Sehgal VN, Jrivastava G. Corticosteroid — irresponsive pemphigus vulgaris following antiepileptic therapy. International Journal of Dermatology 27: 258, 1988
Shackleford EJ, Watson FT. Amiodarone-phenytoin interaction. Drug Intelligence and Clinical Pharmacy 21: 921, 1987
Shaw PN, Houston JB, Rowland M, Hopkins K, Thiercelin JF, et al. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. British Journal of Clinical Pharmacology 20: 611–618, 1985
Sheridan PH, Ashworth M, Milne K, White BG, Santilli N, et al. Open pilot study of felbamate in partial seizures. Epilepsia 27: 649, 1986
Shoeman JF, Elyas AA, Brett EM, Lascelles PT. Altered ratio of carbamazepine-10,11-epoxide/carbamazepine in plasma of children: evidence of antiepileptic drug interaction. Developmental Medicine and Child Neurology 26: 749–755, 1984
Shukla S, Goodwin CD, Long LEG, Miller MG. Lithium-carbamazepine neurotoxicity and risk factors. American Journal of Psychiatry 141: 1604–1606, 1984
Smart HL, Somerville KW, Williams J, Richens A, Longman MJS. The effect of sucrafate upon phenytoin absorption in man. British Journal of Clinical Pharmacology 20: 238–240, 1985
Smith DB, Goldstein SG, Roomet A. A comparison of the toxicity effects of the antiepileptic eterobarb (Antilon, DMMP) and phenobarbital in normal human volunteers. Epilepsia 27: 149–155, 1986
Smith JW, Seidl LG, Cluff LE. Studies on the epidemiology of adverse reactions: V. Clinical factors influencing susceptibility. Annals of Internal Medicine 65: 629–640, 1966
Solomon H, Abrams WB. Interaction between digitoxin and other drugs in man. American Heart Journal 83: 277–280, 1972
Somogyi A, Gugler R. Drug interactions with cimetidine. Clinical Pharmacokinetics 7: 23–41, 1982
Somogyi A, Thielscher S, Gugler R. Influence of phenobarbital treatment on cimetidine kinetics. European Journal of Clinical Pharmacology 19: 343–347, 1981
Sonnen AEH. Oxcarbazepine and oral contraceptives. Abstract G11. Acta Neurologica Scandinavica 82 (Suppl. 133): 37, 1990
Sotaniemi EA, Arvela P, Huhiti E. Increased clearance of tolbutamide from the blood of asthmatic patients. Annals of Allergy 29: 134–141, 1971
Sotaniemi EA, Pelkonen RO, Ahokas J, Pirttiaho HI, Ahlqvist J. Drug metabolism in epileptics: in vivo and in vitro correlations. British Journal of Clinical Pharmacology 5: 71–76, 1978
Spina E, Martines C, Fazio A, Trio R, Pisani F, et al. Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Therapeutic Drug Monitoring 13: 109–112, 1991
Stambaugh JE, Hemphili DM, Wainer IW, Schwartz I. A potential toxic drug interaction between pethidine (meperidine) and phenobarbital. Lancet 1: 398–399, 1977
Sutton G, Kupferberg HJ. Isoniazid as an inhibitor of primidone metabolism. Neurology 25: 1179–1181, 1975
Svendsen TL, Kristensen M, Hansen JM, Skovsted L. The influence of disulfiram on the half-life and metabolic clearance rate of diphenylhydantoin and metabolic clearance rate of diphenylhydantoin and tolbutamide in man. European Journal of Clinical Pharmacology 9: 439–441, 1976
Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, et al. Impaired phenytoin bioavailability secondary to cis-platinum, vinblastin and bleomycin. Therapeutic Drug Monitoring 6: 302–305, 1984
Syversen GB, Morgan JP, Weintraub M, Myers J. Acetazolamide-induced interference with primidone absorption: case report and metabolic studies. Archives of Neurology 34: 80–84, 1977
Tartara CA, Galimberti CA, Manni R, Parietti L, Zucca C, et al. Differential effects of valproic acid and enzyme-inducing antiepileptic drugs on nimodipine pharmacokinetics in epileptic patients. British Journal of Clinical Pharmacology 32: 335–340, 1991
Tassaneeyakul W, Veronese ME, Birkett DJ, Doecke CJ, Mc-Manus ME, et al. Co-regulation of phenytoin and tolbutamide metabolism in humans. British Journal of Clinical Pharmacology 34: 494–498, 1992
Tempelhoff R, Modica PA, Jehlish WS, Spitznagel EL. Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with antiepileptic drugs. Anesthesia and Analgesia 71: 665–669, 1991
Tempelhoff R, Modica PA, Spitznayel EC. Antiepileptic therapy increases fentanyl requirements during anaesthesia for craniotomy. Canadian Journal of Anaesthesia 37: 327–332, 1990
Tennison MB, Miles MV, Pollock GM, Thorn MD, Dupuis RE. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 29: 543–547, 1988
Theisohn M, Heimann G. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. European Journal of Pharmacology 22: 541–551, 1982
Thompson P, Trimble MR. Antiepileptic drugs and cognitive function. Epilepsia 25: 531–544, 1982
Tomson T, Bertilsson L. Potent pharmacological effects of carbamazepine-10,11-epoxide in trigeminal neuralgia. Archives of Neurology 41: 598–601, 1984
Tong TG, Pond SM, Kreek MJ, Jaffry NF, Benowitz NL. Phenytoin induced methadone withdrawal. Annals of Internal Medicine 94: 349–351, 1981
Tonini M, Gatti G, Manzo L, Olibet G, Coccini T, et al. Vigabatrin does not affect the interstinal absorption of phenytoin in rat duodeno-jejunal loops in situ. Pharmacological Research 26: 201–205, 1992
Tsue SE, Moore RG, Ashley JJ, McBride WG. Disposition of synthetic glucocorticoids I. Pharmacokinetics of dexamethasone in healthy adults. Journal of Pharmacokinetics and Biopharmaceutics 7: 249–254, 1979
Twum-Barima Y, Finnigan T, Habash AI, Cape RDT, Carruthers SG. Impaired enzyme induction by rifampicin in the elderly. British Journal of Clinical Pharmacology 17: 595–597, 1984
Valsalan NC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. British Medical Journal 285: 261–262, 1982
van Wieringen A, Vrijlandt CM. Ethosuximide intoxication caused by interaction with isoniazid. Neurology 33: 1227–1228, 1983
Vestal RE, Noms AH, Tobin JD, Cohen DH, Shock NW, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clinical Pharmacology and Therapeutics 18: 425–432, 1975
Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR. Effect of age and cigarette smoking on the disposition of propranalol in man. Clinical Pharmacology and Therapeutics 26: 8–15, 1979
Vincon G, Albin H, Demotes-Mainard F, Guyot M, Bistue C, et al. Effects of josamycin on carbamazepine kinetics. European Journal of Clinical Pharmacology 32: 321–323, 1987
Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Research 11: 147–150, 1992
Warren JW, Benmamen JD, Braxton B, Wannamaker BB, Levy RH. Kinetics of carbamazepine-ethosuximide interaction. Clinical Pharmacology and Therapeutics 28: 646–651, 1980
Wasfi IA, Tanira MOM. The effect of chronic administration of cyclosporin A on phenytoin pharmacokinetic parameters in the rat. Life Sciences 52: 199–204, 1993
Weichbrodt GD, Elliot DP. Treatment of phenytoin toxicity with repeated doses of activated charcoal. Annals of Emergency Medicine 16: 1387–1389, 1987
Wesseling H, Mols-Thurkow I. Interaction of diphenylhydantoin (DPH) and tolbutamide in man. European Journal of Clinical Pharmacology 8: 75–78, 1975
Wilensky AJ, Friel PN, Levy RH, Comfort CP, Kaluzny SP. Kinetics of phenobarbital in normal subjects and epileptic patients. European Journal of Clinical Pharmacology 23: 87–92, 1982
Williams K, Begg E, Wade D, O’shea K. Effects of phenytoin, phenobarbital and ascorbic acid on misonidazole elimination. Clinical Pharmacology and Therapeutics 33: 314–321, 1983
Wright N, Prescott LF. Potentiation by previous drug therapy of hepatotoxicity following paracetamol overdosage. Scottish Medical Journal 18: 56–58, 1973
Wroblewski BA, McColgan K, Smith K, Whyte J, Singer WD. The incidence of seizures during tricyclic antidepressant drug treatment on a brain injured population. Journal of Clinical Psychopharmacology 10: 124–128, 1990
Wroblewski BA, Singer WD, Whyte J. Carbamazepine-erythromycin interaction. Case studies and clinical significance. Journal of American Medical Association 255: 1165–1167, 1986
Yerby MS, Leppik I. Epilepsy and the outcome of pregnancy. Journal of Epilepsy 3: 193–199, 1990
Yokochi K, Yokochi A, Chiba K, Ishizaki T. Phenytoin-allopurinol interaction: Michaelis-Menton kinetic parameters of phenytoin with and without allopurinol in a child with Lesch-Nyhan Syndrome. Therapeutic Drug Monitoring 4: 353–357, 1982
Yu YL, Huang CY, Chin D, Woo E, Chang CM. Interaction between carbamazepine and dextropropoxyphene. Postgraduate Medical Journal 62: 231–233, 1986
Yue CP, Mann KS, Chan KH. Severe thrombocytopenia due to combined cimetidine and phenytoin therapy. Neurosurgery 20: 963–965, 1987
Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. British Journal of Clinical Pharmacology 33: 511–513, 1992
Yukawa E, Higuchi S, Aoyama T. The effect of concurrent administration of sodium valproate on serum concentrations of primidone and its metabolite phenobarbital. Journal of Clinical Pharmacy and Therapeutics 14: 387–392, 1989
Zaccara G, Paganini M, Campostrini R, Moroni F, Valenza T, et al. Effect of associated antiepileptic treatment on valproate-induced hyperammonaemia. Therapeutic Drug Monitoring 7: 185–190, 1985
Zifkin B, Sherwin A, Anderman F. Phenytoin toxicity due to interaction with clobazam. Neurology 41: 313–314, 1991
Zielinski JJ, Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. Therapeutic Drug Monitoring 9: 21–23, 1987
Zielinski JJ, Haidukewych D, Lehata BJ. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Therapeutic Drug Monitoring 7: 51–53, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Patsalos, P.N., Duncan, J.S. Antiepileptic Drugs. Drug-Safety 9, 156–184 (1993). https://doi.org/10.2165/00002018-199309030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199309030-00003